Cytokinetics (CYTK) Prices $700 Million Stock Offering at $71
Published on 5/7/2026

AI Summary
Cytokinetics (CYTK) announced the pricing of its stock offering, raising $700 million by selling shares at $71 each. This offering could be significant as it allows the company to fund its research and development initiatives. The stock price reflects investor interest and market conditions at the time of offering. The move is expected to potentially influence the company's market position and stock performance moving forward.
Related News

Earnings
Abbott Labs (ABT) to Report Q2 Earnings on July 16, Growth Insights
Jun 20

Earnings
Pagaya (PGY) Closes $800 Million Personal Loan ABS Transaction
Jun 20

Earnings
NICE (NICE) Shares See Price Target Cut to $100 Amid Growth Concerns
Jun 20

Earnings
AVO Director Purchases $2.1 Million in Shares, Signals Confidence
Jun 20